RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Progressive Supranuclear Palsy: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
[Coexistence of progressive supranuclear palsy and idiopathic normal pressure hydrocephalus: pathophysiology and response to shunt surgery].
Yamahara Naoki et al., Rinsho shinkeigaku = Clinical neurology (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893877/
- 2.
TGF-β Inhibition Attenuates Tau Accumulation and Neurodegeneration in Progressive Supranuclear Palsy Patient-Derived Organoids.
Talarico Mariagrazia et al., Movement disorders : official journal of the Movement Disorder Society (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888872/
- 3.
MRI-based machine learning models for differentiating Parkinson’s disease and Progressive Supranuclear Palsy
Vilhoubeinuo Veronica Khruomo et al., F1000Research (13 October 2026)
https://doi.org/10.12688/f1000research.190609.1
- 4.
Incident versus prevalent progressive supranuclear palsy: analyses of U.S. Alzheimer's Disease Research Centers data indicate clinical and neuropathological features of a relatively common and underrecognized tauopathy in the aging brain.
Cushing Benjamin J et al., Acta neuropathologica (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42867534/
- 5.
A clinically interpretable model for Parkinson’s disease: insights from complementary MRI modalities
Qianshi Zheng et al., Brain Communications (10 October 2026)
https://doi.org/10.1093/braincomms/fcag383
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426 · Recruiting · Phase 3 · Novartis Pharmaceuticals
Ages 41 to 81
https://clinicaltrials.gov/study/NCT07498426
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Progressive Supranuclear Palsy
Progressive Supranuclear Palsy is a rare brain disease that causes degeneration of cells in the brainstem and cerebral cortex. It is frequently misdiagnosed as Parkinson's disease. Key features include falls, eye movement abnormalities, stiffness, and cognitive changes. There is no disease-modifying treatment and median survival after diagnosis is 6-7 years.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
This review aims to summarize the frequency, pathophysiological features, and therapeutic effectiveness of shunt surgery in cases of coexisting progressive supranuclear palsy (PSP) and idiopathic normal pressure hydrocephalus (iNPH). In this review, we showed that the coexistence of these two disorders is not rare, that they may be related through the glymphatic system, and that in cases clinically suspected of having both conditions, improvement after shunt surgery may persist for one year or more, whereas in six pathologically confirmed cases, the duration of improvement was one year or less. However, the clinical characteristics of shunt-responsive patients among cases clinically suspected of having both conditions remain unclear. To address this issue, we are conducting a multicenter observational study to validate the usefulness of reduced frontal lobe blood flow on cerebral perfusion single-photon emission computed tomography, as previously reported.
Common Questions
What is Progressive Supranuclear Palsy?
Progressive Supranuclear Palsy is a rare brain disease that causes degeneration of cells in the brainstem and cerebral cortex. It is frequently misdiagnosed as Parkinson's disease. Key features include falls, eye movement abnormalities, stiffness, and cognitive changes. There is no disease-modifying treatment and median survival after diagnosis is 6-7 years.
How many clinical trials are available for Progressive Supranuclear Palsy?
RareWays currently indexes 100 clinical trials for Progressive Supranuclear Palsy, of which 14 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Progressive Supranuclear Palsy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Progressive Supranuclear Palsy.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.